news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

the latest "top 100 chinese pharmaceutical innovation enterprises" have jointly verified the survival truth under cyclical shocks: innovation is the foundation of science, differentiation is the foundation of business, and profit is the foundation of investment.

the companies on the list of "top 100 chinese pharmaceutical innovation companies" have changed significantly compared with previous years. however, regardless of whether the companies are ranked up or down, or enter or leave the list, this list shows the efforts of all participants in the great competition of chinese pharmaceutical industry innovation, and the profound practice of pursuing sustainable industrial innovation capabilities in the next decade.

the "top 100 chinese pharmaceutical innovation companies in 2024" (hereinafter referred to as the "top 100 innovative companies") was released by e-drug manager based on clarivate analytics' derwent innovation™ patent data and cortellis™ competitive intelligence and clinical trial data, using a "three-dimensional and four-indicator" selection system. after several months of data screening, integrated analysis.

since 2019, e-drug manager has been building models, collecting and organizing data, starting from the current situation of pharmaceutical innovation, with enterprises as the main body and hard data as the basis. through the three dimensions of innovation foundation, innovation process and innovation results, and using the number of authorized patents, total number of patent citations, number of clinical trials and number of innovative drugs approved and launched as the evaluation basis, it selects the "top 100 chinese pharmaceutical innovation enterprises" representing china's pharmaceutical innovation strength every year.

to date, this is the sixth time that e-drug manager has released the list of "top 100 chinese pharmaceutical innovation companies".

overall, most of the “top 100 innovators” have done the same thing in the past year: using “self-research + strengthening bd” to extend their strengths, make up for their weaknesses, achieve endogenous evolution, embrace partners, and pursue internationalization.

looking specifically at the companies on the list, the unchanging trend is that the rankings of the top companies remain relatively stable, while the bottom companies are more active.

for the 25 companies in the first tier, there were relatively few overall changes. the top ten companies performed the most stably, with hengrui medicine and beigene still ranking in the top two; innovent biologics has remained in fifth place for three consecutive years; china biologic products, rongchang biopharmaceuticals, akeso biopharmaceuticals, fosun pharma, tasly, and lunan pharmaceutical have all risen in ranking compared to last year.

baili tianheng, luye pharma, junshi biosciences and hisun pharmaceutical have successfully moved from the second echelon last year to the first echelon, especially baili tianheng, which has entered the top ten for the first time.

another continuing trend is that the number of local pharma companies in the “top 100 innovators” is still growing.

from 2020 to 2022, the number of pharma companies in the top 100 decreased year by year, but doubled in 2023. this shows that in the context of the "capital winter" and the slowdown in the development of biotech, pharma relied on cash reserves and used bd and other methods to accelerate its innovative transformation, and this growth trend continued this year.

this year, there are 24 new companies on the list, which is the same number as in previous years, such as kelun botai, quanxin bio, yiling pharmaceutical, enhua pharmaceutical, chengdu pioneer, yifan pharmaceutical, china resources sanjiu and dong-e e-jiao.

among them, sinopharm, a representative of the vaccine "national team", entered the list for the first time and directly ranked among the first echelon; among the new companies on the list, chinese medicine companies are the largest, and some companies with leading investment in innovative research and development have shown results in innovation and transformation; yuanda pharmaceutical, which has achieved a full industrial chain layout and has achieved particularly obvious results in innovation and transformation in the past two years, entered the list for the first time; some star biotech companies whose products have been successfully licensed-out or have gone overseas independently were selected as the "top 100 innovators".

fortunately, among the "top 100 innovators", nearly 30 companies have "upgraded" in ranking compared with last year. most of the companies that have risen in ranking have made key clinical progress in the process of optimizing their pipelines.

of course, there are also companies whose rankings have fallen sharply.

the past year was an extreme test for whether pharmaceutical companies could survive the "capital winter" by rationally adjusting resources and management capabilities. it verified the company's ability to respond to its own role and positioning, its efficiency in operational reforms and refined management, and whether it had absolutely differentiated product value.

however, due to the different growth paths of pharmaceutical companies, different cash reserves and financing capabilities, coupled with the uncertainty of new drug research and development, the time and method of achieving breakthroughs will also be unique. horizontally and vertically, these companies may have obvious differences in their performance in research and development. those companies whose rankings have dropped significantly have seen a reduction in the number of clinical trials to varying degrees.

in addition, from the perspective of regional distribution, according to the industrial and commercial registration information, there are 43 companies in the yangtze river delta, 19 in the beijing-tianjin-hebei region, 11 in the pearl river delta, and 27 in other regions on the list in 2024. the three major urban agglomerations account for 73%, which is slightly lower than last year, but still highlights the advantages of industrial cluster development.

in terms of the total number of clinical trials, the top four companies are hengrui medicine, beigene, china biopharmaceuticals, and cspc pharmaceutical group. clinical trials are an inevitable stage in pharmaceutical innovation, and the number and stage distribution of clinical trials can reflect the innovation capabilities and scale of companies. an obvious feature is that the top ten companies in the "top 100 innovators" have a relatively rich product pipeline that has entered phase ii clinical trials.

judging from the number of authorized patents, most of the companies with the most patents are first-tier domestic companies in innovation and transformation, proving their strong innovation roots.

taking 2015 as a new milestone of innovation, 2024 is the tenth year. standing at the starting point of the decade of innovation, judging the trends of the next decade, we need to focus on "innovation 100" - the first camp of forces that can represent china's pharmaceutical innovation capabilities, focus on opportunities and victories, and start a more determined next decade.